Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Recordati SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Recordati SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Recordati SpA, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Recordati Acquires Rights to Cystagon from Mylan 13
Recordati Acquires Consumer Health Brands from Bayer Consumer Care 14
Recordati Acquires Rights for Seloken from Astrazeneca 15
Recordati Rare Diseases Acquires North American Rights to Cystadane 16
Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For US$100 Million 17
Recordati Completes Acquisition Of Portfolio Of Products From Akvion For US$87 Million 19
Recordati Acquires Dentosan Line Of Oral Care Products From Cilag 21
Recordati Acquires Six Over The Counter Products From Cilag And McNeil 22
Private Equity 23
CVC Fund to Acquire Majority Stake in Recordati for USD3.5 Billion 23
Partnerships 25
Recordati and Plethora Enter into Co-Development Agreement with Pharmaserve for PSD502 25
Prasco Labs Enters into Distribution Agreement with Recordati Rare Diseases 26
Ony Enters Into Co-Promotion Agreement With Recordati Rare Diseases For NeoProfen 27
Licensing Agreements 28
Recordati Enters into Licensing Agreement with MimeTech 28
Recordati Enters into Licensing Agreement with Meyer Hospital 29
Recordati Enters into Licensing Agreement with Gedeon Richter for Cariprazine 30
Recordati Enters into Licensing Agreement with Assistance Publique – Hopitaux de Paris 31
Apricus Biosciences Enters Into Licensing Agreement With Recordati For Vitaros 32
Erytech Pharma enters into Licensing Agreement with Orphan Europe for Graspa 33
Recordati Amends Licensing Agreement with Plethora Solutions for Fortacin 34
Plethora Enters into Licensing Agreement with Recordati for PSD502 36
Gebro Pharma Enters Into Licensing Agreement With Recordati For Kentera 38
Acquisition 39
Recordati Acquires Pro Farma for USD16.2 Million 39
Recordati Acquires Italchimici for up to USD145 Million 40
Recordati Completes Acquisition of 90% Interest in Opalia Pharma for USD37.6 Million 41
Recordati Completes Acquisition Of Laboratorios Casen Fleet From C.B. Fleet For US$122.5 Million 43
Recordati Completes Acquisition Of Farma-Projekt For US$21 Million 45
Recordati SpA – Key Competitors 46
Recordati SpA – Key Employees 47
Recordati SpA – Locations And Subsidiaries 48
Head Office 48
Other Locations & Subsidiaries 48
Recent Developments 51
Financial Announcements 51
Oct 30, 2018: Recordati announces sales and margin growth in the first nine months 2018. revenues +5.1%, ebitda +11.1%, operating income +9.6%, net income +8.2%. interim dividend € 0.45 (+7.1%). 51
Jul 26, 2018: Recordati announces sales and margin growth in the first half 2018. Revenues +6.9%, operating income +14.1%, net income +11.7% 52
May 08, 2018: Recordati Announces Sales and Margin Growth in the First Quarter 2018 53
Mar 15, 2018: Recordati: Board Approves The 201 7 Accounts 54
Feb 08, 2018: Recordati: Preliminary 2017 Results Confirm Continued Growth of Sales and Profitability. Sales +11.6%, Operating Income +24.1%, Net Income +21.6% 57
Oct 26, 2017: Recordati: Very Good Results in the First Nine Months 2017. Continued Growth in Sales +11.8%, Operating Income +21.8%, Net Income +20.6%. Interim Dividend € 0.42 (+20%) 58
Jul 27, 2017: Recordati: Very Good Results In The First Half 2017. Continued Growth In Sales +10.7%, Operating Income +19.4%, Net Income +19.8% 60
May 04, 2017: Recordati: Excellent Results in the First Quarter 2017. Continued Growth in Sales +13.1%, Operating Income +19.0%, Net Income +19.9% 62
Mar 01, 2017: Recordati: Board Approves The 2016 Accounts. Sales € 1,153.9 Million (+10.1%), Operating Income € 327.4 Million (+17.6%) And Net Income € 237.4 Million (+19.4%). 2016 Dividend € 0.70 (+16.7%) 63
Feb 09, 2017: Recordati: Preliminary 2016 Results Confirm Continued Growth Of Revenues And Profitability 66
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67
Recordati SpA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Recordati SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Recordati SpA, Deals By Therapy Area, 2012 to YTD 2018 9
Recordati SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Recordati Acquires Rights to Cystagon from Mylan 13
Recordati Acquires Consumer Health Brands from Bayer Consumer Care 14
Recordati Acquires Rights for Seloken from Astrazeneca 15
Recordati Rare Diseases Acquires North American Rights to Cystadane 16
Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For US$100 Million 17
Recordati Completes Acquisition Of Portfolio Of Products From Akvion For US$87 Million 19
Recordati Acquires Dentosan Line Of Oral Care Products From Cilag 21
Recordati Acquires Six Over The Counter Products From Cilag And McNeil 22
CVC Fund to Acquire Majority Stake in Recordati for USD3.5 Billion 23
Recordati and Plethora Enter into Co-Development Agreement with Pharmaserve for PSD502 25
Prasco Labs Enters into Distribution Agreement with Recordati Rare Diseases 26
Ony Enters Into Co-Promotion Agreement With Recordati Rare Diseases For NeoProfen 27
Recordati Enters into Licensing Agreement with MimeTech 28
Recordati Enters into Licensing Agreement with Meyer Hospital 29
Recordati Enters into Licensing Agreement with Gedeon Richter for Cariprazine 30
Recordati Enters into Licensing Agreement with Assistance Publique - Hopitaux de Paris 31
Apricus Biosciences Enters Into Licensing Agreement With Recordati For Vitaros 32
Erytech Pharma enters into Licensing Agreement with Orphan Europe for Graspa 33
Recordati Amends Licensing Agreement with Plethora Solutions for Fortacin 34
Plethora Enters into Licensing Agreement with Recordati for PSD502 36
Gebro Pharma Enters Into Licensing Agreement With Recordati For Kentera 38
Recordati Acquires Pro Farma for USD16.2 Million 39
Recordati Acquires Italchimici for up to USD145 Million 40
Recordati Completes Acquisition of 90% Interest in Opalia Pharma for USD37.6 Million 41
Recordati Completes Acquisition Of Laboratorios Casen Fleet From C.B. Fleet For US$122.5 Million 43
Recordati Completes Acquisition Of Farma-Projekt For US$21 Million 45
Recordati SpA, Key Competitors 46
Recordati SpA, Key Employees 47
Recordati SpA, Subsidiaries 48
List of Figures
Recordati SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Recordati SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9